CBMG newsroom

May 2, 2023

news

CBMG Announces Exclusive Collaboration and License Agreement with Janssen to Develop and Commercialize anti CD19 & CD20 Bi-Specific and anti CD20 CAR-Ts for Non-Hodgkin Lymphoma
Oct 31, 2022

Technology

CBMG Announces FDA Clearance of IND Application for Novel TIL Therapy C-TIL051
Jan 12, 2022

Technology

CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations
Dec 13, 2021

Technology

CBMG Receives FDA Clearance of IND Application for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Sep 30, 2021

news

CBMG Holdings Completes $120 Million in Series A Funding
Feb 19, 2021

Events

Cellular Biomedicine Group, Inc. Announces Completion of Merger

PDF VERSION
Feb 8, 2021

Events

CBMG Stockholders Approve Merger

PDF VERSION
Jan 28, 2021

Events

Leading Proxy Advisory Firms Glass Lewis and ISS Recommend CBMG Stockholders Vote FOR Proposed Merger

PDF VERSION
Dec 4, 2020

Events

CBMG Announces Data to be Presented at 2020 ASH Annual Meeting

PDF VERSION
Nov 9, 2020

Financial Reports

CBMG Reports Q3 2020 Financial Results and Business Highlights

PDF VERSION
Aug 26, 2020

Events

CBMG to Present at Chinese Biopharmaceutical Association-USA Annual Conference
Aug 12, 2020

Events

Cellular Biomedicine Group (CBMG) Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

PDF VERSION
Aug 12, 2020

Financial Reports

CBMG Reports Q2, H1 2020 Financial Results and Business Highlights

PDF VERSION
Jul 13, 2020

Events

CBMG Hosts R&D Showcase and Provides Updates to Clinical Programs

PDF VERSION
Jun 30, 2020

Events

CBMG to Host Investor R&D Showcase Highlighting Updates to Clinical Programs

PDF VERSION

CBMG

News Room

CBMG Announces Exclusive Collaboration and License Agreement with Janssen to Develop and Commercialize anti CD19 & CD20 Bi-Specific and anti CD20 CAR-Ts for Non-Hodgkin Lymphoma

CBMG Announces FDA Clearance of IND Application for Novel TIL Therapy C-TIL051

CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations

CBMG Receives FDA Clearance of IND Application for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

CBMG Holdings Completes $120 Million in Series A Funding

Cellular Biomedicine Group, Inc. Announces Completion of Merger

CBMG Stockholders Approve Merger

Leading Proxy Advisory Firms Glass Lewis and ISS Recommend CBMG Stockholders Vote FOR Proposed Merger

CBMG Announces Data to be Presented at 2020 ASH Annual Meeting

CBMG Reports Q3 2020 Financial Results and Business Highlights

CBMG to Present at Chinese Biopharmaceutical Association-USA Annual Conference

Cellular Biomedicine Group (CBMG) Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

CBMG Reports Q2, H1 2020 Financial Results and Business Highlights

CBMG Hosts R&D Showcase and Provides Updates to Clinical Programs

CBMG to Host Investor R&D Showcase Highlighting Updates to Clinical Programs

Newsletter